Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood  by Gartenmann, Anne C. et al.
Kidney International, Vol. 64 (2003), pp. 1450–1454
Better renoprotective effect of angiotensin II antagonist
compared to dihydropyridine calcium channel
blocker in childhood
ANNE C. GARTENMANN, EMILIO FOSSALI, RODO O. VON VIGIER, GIACOMO D. SIMONETTI,
JAN SCHMIDTKO, ALBERTO EDEFONTI, and MARIO G. BIANCHETTI
Division of Nephrology, University Children’s Hospital, Inselspital, Bern, Switzerland; Pediatric Renal Unit, University of Milan
Medical School, Clinica De Marchi, Milan, Italy; and Department of Pediatrics, San Giovanni Hospital, Bellinzona, Switzerland
Better renoprotective effect of angiotensin II antagonist com-
pared to dihydropyridine calcium channel blocker in childhood.
Background. The dihydropyridine calcium channel blocker
amlodipine and the angiotensin II antagonist irbesartan effec-
tively reduce blood pressure in hypertensive children.
Methods. Eligible for the open-label, randomized study were
nephropathic children between 6.0 and 18 years of age with
plasma creatinine 177 mol/L, overt proteinuria, untreated
arterial hypertension (systolic, 5 to 30 mm Hg; and diastolic,
1 to 15 mm Hg; 95th centile) and stable immunosuppressive
treatment. The initial dose of amlodipine was 5 mg (body weight,
20 to 40 kg) and 10 mg (body weight, 40 kg), respectively,
that of irbesartan, which was 75 mg (body weight, 20 to 40 kg)
and 150 mg (body weight, 40 kg), respectively. The dosage
was doubled if necessary.
Results. A total of 26 children aged 6.1 to 17 years were
allocated to receive either amlodipine (N  13) or irbesartan
(N  13) for 16 weeks. Severe edema and headache occurred
in two patients on amlodipine who withdrew from the study.
No adverse experiences were noted in patients given irbesartan.
Amlodipine [by 12 (10 to 14)/7 (5 to 10) mm Hg; median and
interquartile range, respectively] and irbesartan [by 13 (9 to 16)/9
(7 to 11) mm Hg, respectively] reduced blood pressure (P 
0.01) in a similar fashion. Heart rate, plasma sodium, and creati-
nine did not change. Irbesartan slightly increased plasma potas-
sium [by 0.1 (0.0 to 0.2) mmol/L; P  0.05]. Plasma albumin
and the urinary albumin/creatinine ratio were similar before and
with amlodipine. On the contrary, irbesartan increased plasma
albumin [by 4 (3 to 5) g/L; P 0.03] and decreased the urinary
albumin/creatinine ratio [by 242 (68 to 312) mg/mmol; P 0.03].
Conclusion. The study demonstrates that in children the
effect of angiotensin II antagonists on proteinuria is better
than that of dihydropyridine calcium channel blockers.
Key words: hypertension, childhood, kidney disease, proteinuria, cal-
cium channel blocker, angiotensin II antagonist, irbesartan, amlodi-
pine.
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Progression of chronic kidney diseases is largely due to
secondary factors rather than the activity of the underlying
diseases. Two cornerstones in prevention of progression
are control of blood pressure and reduction of pathologic
proteinuria [1–4]. The dihydropyridine calcium channel
blocker amlodipine [5] and the angiotensin II antagonist
irbesartan [6] are two orally available antihypertensive
drugs that are generally well tolerated. Recent observa-
tions in hypertensive children show that once a day treat-
ment with either amlodipine [7–13] or irbesartan [14–16]
effectively reduces blood pressure over a full period of 24
hours. As a consequence, the mentioned agents currently
emerge as first-line therapy in the management of child-
hood hypertension.
In children, arterial hypertension is rather rare and
mostly secondary to kidney diseases [17]. There are no
studies comparing the value of dihydropyridine calcium
channel blockers and drugs that block the renin-angio-
tensin II-aldosterone system in children with chronic
kidney diseases. The purpose of the present 16-week,
open-label trial was to evaluate blood pressure and albu-
minuria in white children with chronic kidney diseases
and overt proteinuria randomly allocated to receive ei-
ther amlodipine or irbesartan.
METHODS
Eligible for the open-label, short-term, randomized
study were patients of both genders between 6.0 and
18 years of age with a body weight of 20 kg or more,
established nondiabetic chronic kidney disease (more
than 6 months), normal or slightly increased plasma cre-
atinine (less than 177 mol/L), urinary protein concen-
tration more than 300 mg/L on early morning urine (by
indicator dye-binding test), untreated (more than 6 weeks)
arterial [18] hypertension (systolic values 5 to 30 mm Hg
and diastolic values 1 to 15 mm Hg above 95th centile
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for age, length, and gender), and stable (more than 12
weeks) immunosuppressive treatment. Female subjects
of childbearing potential were not considered eligible be-
cause of the possible fetal and neonatal toxicity [14, 16].
After a 6-week washout and run-in period ( baseline)
and 16 weeks after starting amlodipine and irbesartan,
respectively, blood pressure, heart rate, and body weight
were measured and blood taken for the determination
of hemoglobin, sodium, potassium, creatinine, uric acid,
albumin, aminotransferase, and creatine kinase. Albumin
and creatinine were determined on early morning urine
during 3 consecutive days both before and with amlodi-
pine and irbesartan, respectively; the average of the three
determinations was used for analysis. Finally, the patients
were monitored by a written questionnaire both before
as well as on study medication for the presence of abdom-
inal pain, back pain, constipation, cough, diarrhea, edema,
fatigue, headache, insomnia, orthostasis, and rash.
Sitting (10 minutes) blood pressure and heart rate
were obtained using semiautomatic oscillometric record-
ers and a cuff covering approximately three fourths of
the upper arm length from the acromion to the olecra-
non. The mean of three consecutive measurements in
which diastolic pressures differed by less than 5 mm Hg
was recorded. The effect of amlodipine and irbesartan,
respectively, on blood pressure was evaluated 24 hours
postdose.
Amlodipine and irbesartan were delivered once a day
by commercially available tablets (amlodipine, 5 and
10 mg; irbesartan, 75, 150, and 300 mg) on awakening.
The initial dose of amlodipine was 5 mg (body weight
between 20 and 40 kg) and 10 mg (body weight more than
40 kg), respectively, that of irbesartan 75 mg (body weight
between 20 and 40 kg) and 150 mg (body weight more
than 40 kg), respectively. The dosage of amlodipine and
that of irbesartan was doubled if necessary by the follow-
ing criteria: (1) failure to decrease systolic blood pressure
by at least 10 mm Hg after 3 to 5 weeks or (2) systolic
or diastolic blood pressure above the 95th centile for body
length and gender after 8 to 12 weeks [8, 13, 14, 16].
Pill count and pharmacy records were used to assess
adherence to the treatment. The measured blood pres-
sure values (systolic or diastolic), subsequently reported
to be as “measured,” and the corresponding 95th centile
for age, length, and gender, subsequently reported to as
“95th centile” [18], were used to express the severity of
hypertension using following equations [19]: (1) value
above 95th centile  measured – 95th centile; and (2)
relative hypertension  value above 95th centile/95th
centile.
The ethics committees of the participant centers ap-
proved the protocol, and the children and their families
gave informed consent to the study. The results are given
either as median and interquartile range (which extends
from the value at 25th centile to that at 75th centile and
Table 1. Characteristics of the 26 patients with chronic kidney
diseases included in the triala
Amlodipine Irbesartan
group group
Number 13 13
Gender female:male 5:8 7:6
Ageb years 11 (8.9–14) 12 (8.1–13)
Heightb m 1.44 (1.34–1.49) 1.46 (1.27–1.61)
Plasma creatinine number
Normal 9 8
Slightly increased 4 5
Underlying condition number
Hemolytic-uremic syndrome 3 2
IgA nephropathy 1 2
Polycystic kidney disease 2 1
Reflux nephropathy 2 1
Familial juvenile
nephronophthisis — 2
Focal and segmental
glomerular sclerosis 2 —
Idiopathic membranous
glomerulonephritis 1 1
Renal hypodysplasia — 2
Alport syndrome 1 —
Membranoproliferative
glomerulonephritis — 1
Systemic lupus
erythematosus 1 —
Wegener’s granulomatosis — 1
a Immunosuppressive agents were given to one of the patients with IgA ne-
phropathy (prednisone and cyclophosphamide) included in the irbesartan group,
to the patient with idiopathic membranous glomerulonephritis (prednisone) in-
cluded in the amlodipine group, to the patient with systemic lupus erythematosus
(prednisone and cyclophosphamide), and to the patient with Wegener’s granulo-
matosis (prednisone and cyclophosphamide)
b Median and interquartile ranges
includes half of the data points) or as relative frequency.
Comparison of values before and with treatment with
amlodipine and irbesartan, respectively, was made using
the nonparametric Wilcoxon matched paired signed rank
sum test and the McNemar change test. Comparison of
values obtained with amlodipine and irbesartan was
made using the nonparametric Mann-Whitney-Wilcoxon
rank sum test for two independent samples and the 2-
test. Statistical significance was set at P  0.05.
RESULTS
Twenty-six white outpatients aged from 6.1 to 17 years,
median 12 years, entered the study between 2000 and
2001. Each of the 13 patients were randomized to receive
amlodipine or irbesartan for 16 weeks. Their charac-
terteristics appear in Table 1. Administration of amlodi-
pine was associated with the occurrence of severe edema
and headache in two patients (each in one girl and one
boy, aged 7.0 and 8.2 years, respectively), who withdrew
from the study.
Baseline values were similar in the two groups of pa-
tients (Table 2). The urinary albumine/creatinine ratio
was 41% higher in the irbesartan group than in the am-
lodipine group but not statistically different between the
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ne groups. The initial amlodipine dose of 0.19 (0.16 to 0.22)
mg/kg body weight once a day [6.2 (4.5 to 7.0) mg/m2
body surface area] was doubled in 8 of the 11 patients
who brought the study to completion, while the initial
irbesartan dose of 2.9 (2.3 to 3.1) mg/kg body weight
once a day [87 (65 to 96) mg/m2 body surface area] was
doubled in 10 of the 13 patients. At the end of the study,
the dose of amlodipine was 0.33 (0.26 to 0.38) mg/kg
once a day [9.0 (7.9 to 13.0) mg/m2 body surface area]
and that of irbesartan was 4.8 (3.8 to 5.9) mg/kg once a
day [132 (122 to 179) mg/m2 body surface area].
Medication with irbesartan slightly, but not sig-
nificantly, decreased hemoglobin from 117 to 115 g/L
(Table 2). Plasma potassium, which was not influenced
by the use of amlodipine, slightly, but significantly, in-
creased by 0.1 (0.0 to 0.2) mmol/L during medication
with irbesartan. In only two patients, plasma potassium
increased by more than 0.5 mmol/L. A similar blood
pressure reduction was noted on treatment with amlodi-
pine [by 12 (10 to 14)/7 (5 to 10) mm Hg] and irbesartan
[by 13 (9 to 16)/9 (7 to 11) mm Hg]. At the end of the
study, systolic or diastolic blood pressure was still above
the corresponding 95th centile for age, length, and gen-
der in 8 of the 11 patients treated with amlodipine and in
9 of the 13 patients treated with irbesartan. The administra-
tion of amlodipine did not significantly influence plasma
albumin and the urinary albumin/creatinine ratio. On the
contrary, the use of irbesartan was associated with a
significant increase in plasma albumin [by 4 (3 to 5) g/L]
and a decrease in the urinary albumin/creatinine ratio [by
242 (68 to 312) mg/mmol]. The urinary albumin excretion
decreased by more than 10% (from 19 to 94) in 9 of the
13 patients given irbesartan.
No relevant adverse clinical experiences were noted
in the 11 patients given amlodipine who brought the study
to completion and in the 13 patients given irbesartan.
The adverse clinical experiences noted in the 26 outpa-
tients who entered the study are given in Table 3. Amino-
transferases and creatine kinase were similar before and
with amlodipine and irbesartan, respectively.
DISCUSSION
In chronic kidney diseases, two pivotal factors in pre-
vention of progression are control of blood pressure and
reduction of pathologic proteinuria [1–4]. The present
short-term, randomized trial in nephropathic children
with untreated arterial hypertension and overt protein-
uria shows that the dihydropyridine calcium channel
blocker amlodipine and the angiotensin II antagonist
irbesartan share a similar antihypertensive effect. In ad-
dition, the study clearly shows that irbesartan lowers
urinary protein excretion notably more than amlodipine.
Finally, the present data suggest that irbesartan is better
tolerated than amlodipine.
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Table 3. Adverse clinical experiences and laboratory safety values
(aminotransferases and creatine kinase) after a 6-week washout
and run-in period ( baseline) and with amlodipine or irbesartan,
respectively, in 26 pediatric patients with chronic kidney diseases
Amlodipine Irbesartan
(N  13) (N  13)
Before With Before With
Adverse clinical experiences
Abdominal pain 1 1 1 1
Back pain 1 0 1 1
Constipation 1 1 0 0
Cough 2 1 2 1
Diarrhea 1 0 2 2
Edema 0 2a 0 0
Fatigue 2 2 0 0
Headache 0 2a 1 0
Insomnia 0 0 0 0
Myalgia 0 0 0 0
Orthostasis 1 1 2 0
Rash 0 0 0 0
Patients with adverse experiences 6 7 8 7
Pathologically increased safety values
Alanine aminotransferase 2 2 1 0
Aspartate aminotransferase 1 1 1 1
Creatine kinase 0 1 1 1
a Edema and headache occurred in two patients given amlodipine (each in
one girl and one boy, aged 7.0 and 8.2 years, respectively), who withdrew from
the study
The different effects of amlodipine and irbesartan on
urinary protein excretion are important considering that
proteinuria, in itself, plays a pathogenic role in the pro-
gression of chronic kidney diseases [1–4]. In this regard,
agents that lower proteinuria are more likely to preserve
renal function than those without an effect on protein-
uria. The results of the present study support those of large
trials performed in adults. These studies indicate that
drugs reducing the activity of the renin-angiotensin II-
aldosterone system are more effective than most other
antihypertensive drugs in lowering urinary protein excre-
tion [20, 21]. The antiproteinuric effects of these drugs
may result either from changes in renal hemodynamics,
from a direct effect on glomerular barrier permselectivity,
or both [1–4, 20, 21]. The rationale behind the antiprotein-
uric effect mediated by changes in renal hemodynamics
is the observation in animals that protein ultrafiltration
varies directly with the glomerular capillary pressure.
Thus, the finding that converting enzyme inhibitors and
angiotensin II receptor blockers reduce urinary protein
excretion is consistent with a fall in glomerular capillary
pressure [1–4, 20, 21]. The significance of glomerular
capillary pressure is illustrated by reports of humans with
glomerular disease who have concurrent unilateral renal
artery stenosis; these subjects develop unilateral glomer-
ular disease, as the hypoperfused kidney is protected
[22, 23]. On the other side, clearance studies in subjects
infused neutral dextran indicate that converting enzyme
inhibitors and angiotensin II receptor blockers also ame-
liorate urinary protein excretion via a primary action on
intrinsic glomerular membrane permeability to macro-
molecules [24, 25].
In this study, irbesartan had fewer side effects than
amlodipine, as previously reported in the literature [6].
This observation further supports the use of irbesartan,
considering that undesirable effects of treatment are ma-
jor obstacles to good adherence to prescribed medication
[26]. The present study confirms the potential of angio-
tensin II antagonists to slightly but significantly increase
plasma potassium. Although angiotensin II antagonists,
like converting enzyme inhibitors, generally raise plasma
potassium by less than 0.5 mmol/L, more prominent hyp-
erkalemia sometimes occurs in kidney diseases [27].
The success and widespread use of amlodipine and
irbesartan are related to their attractive pharmakokinetic
profiles. Amlodipine and irbesartan are low-clearance,
hepatically metabolized drugs with high oral bioavail-
ability and a long elimination half-time that is not altered
in kidney disease. Furthermore, these compounds do
not require biotransformation for their pharmacologic
activity [5, 6, 15]. In the present study, the final dose of
amlodipine (0.33 mg/kg body weight once a day) was
slightly higher than in the corresponding pediatric litera-
ture (from 0.12 to 0.29 mg/kg body weight once a day)
and in adults (20 mg once a day, corresponding approxi-
mately to 0.29 mg/kg body weight) [5, 7–13]. Headache,
dizziness, flushing, and peripheral edema are the most
common side effects in subjects given amlodipine [5].
Our patients who developed peripheral edema on am-
lodipine discontinued the compound. Instead, lower am-
lodipine doses or amlodipine reduction were recently
suggested [11]. Similarly, the final dose of irbesartan in
the present study (4.8 mg/kg body weight once a day)
was higher than that reported in the pediatric literature
(from 2.0 to 4.1 mg/kg body weight once a day) and in
adults (300 mg once a day, corresponding approximately
to 4.3 mg/kg body weight) [6, 14–17]. Despite the high
dose, our patients tolerated irbesartan very well.
The small number of patients included in the study
relates to the rather severe inclusion criteria (untreated
hypertensive children with overt proteinuria) and to the
fact that preliminary experience by some of us demon-
strates that the antiproteinuric effect of irbesartan is
statistically significant when the compound is adminis-
tered in at least 10 patients [14].
African Americans are generally more responsive to
calcium channel blockers than to drugs that reduce the
activity of the renin-angiotensin II-aldosterone system.
However, more recent data show that also in African
Americans this therapy has a superior antiproteinuric
effect than calcium antagonism. Nonetheless, African
American patients often require higher doses than white
patients [28].
It has been stated that in adults with chronic kidney
diseases the combination of a calcium channel blocker
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and a drug reducing the activity of the renin-angiotensin
II-aldosterone system more effectively reduces blood
pressure and urinary protein excretion than the individ-
ual components but this statement is much better docu-
mented for nondihydropyridine than for dihydropyridine
calcium channel blockers [29, 30].
The pharmacologic management of childhood hyper-
tension has been characterized by a lack of data on how
best to use antihypertensive agents [17]. The present trial
in children with arterial hypertension and overt protein-
uria shows that amlodipine and irbesartan share a similar
antihypertensive effect. The study also shows that irbe-
sartan is more effective than amlodipine in reducing pro-
teinuria.
CONCLUSION
The study represents yet another link in the chain of
data suggesting an advantageous effect on proteinuria of
drugs that reduce the activity of the renin-angiotensin II-
aldosterone system over dihydropyridine calcium chan-
nel blockers.
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